Cross-Cancer Circulating Proteins for the Prognosis of Primary and Metastatic Liver Cancer Treated with Local Ablation: Post Hoc Exploratory Analysis of the ESTIMATE Trial
Radiology: Imaging Cancer, 2026
Nardone L., Öcal E., Salvermoser L., Fabritius M., Puhr-Westerheide D., Stechele M., Corradini S., Ricke J., Wildgruber M., Alunni-Fabbroni M., Seidensticker M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
A circulating three-protein panel predicted response and survival after liver ablation across patients with primary and metastatic cancers, providing a novel tool to refine patient selection for liver-directed therapies.